ISN WEBINAR: A LOOK AT THE CURRENT STATE OF ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) IN IGAN AND THEIR FUTURE

  • Register
    • Non-member - Free!
    • Member - Free!
    • Subscriber - Free!
    • Free trial - Free!

IgA nephropathy is one of the most common glomerular diseases worldwide affecting young adults with many ended up with kidney failure requiring dialysis or kidney transplantation. Through two experts in this field, the webinar will focus on endothelin (ET) systems and endothelin receptor antagonist (ERAs) in treatment for IgA nephropathy (IgAN). We will take a deeper look at the pathomechanisms of ET-1 and the role of ERAs in kidney disease, and an overview of the current trial evidence of ERAs. The webinar will then offer a panel discussion on the topic, questions are welcome.

 Learning objectives:

- The pathomechanisms of ET system and ERAs in kidney disease
- Review current trial evidence of ERAs in kidney disease
- Understanding the future of ERAs

Muh Geot Wong

Australia

Hiddo Lambers Heerspink

Netherlands

Wei Chen

China

Donald Kohan

USA

Key:

Complete
Failed
Available
Locked
ISN Webinar: A look at the current state of endothelin receptor antagonists (ERAs) in IgAN and their future
Open to view video.  |   Closed captions available
Open to view video.  |   Closed captions available